SecBot SecBot
S-3 ·Filed May 4, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-204130
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

The massive shelf and ATM signal severe financial distress. Short-sellers should watch for actual ATM sales (daily volume reveals). Long holders face extreme dilution risk. Expect continued downward pressure as the market prices in future equity issuance. Monitor insider selling and any new drug catalysts that could offset dilution.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.41
T+0 close · May 4, 2026 · via day close
Latest settled
−25.50%
T+60 · $7.01
Vs SPY
−28.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $9.41entry
  2. T+1 · 7mo ago −4.14%α −5.53% · $9.02
  3. T+5 · 6mo ago −5.26%α −7.24% · $8.92
  4. T+20 · 6mo ago −1.91%α −6.87% · $9.23
  5. T+60 · 4mo ago −25.50%α −28.24% · $7.01

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm filed a $400M universal shelf registration (including a $100M ATM) representing ~202% of its $198M market cap. The company's auditor flagged substantial doubt about its ability to continue as a going concern, and the massive potential dilution signals severe capital needs. This is a highly dilutive and desperate capital raise for a struggling commercial-stage biotech.

Key Facts

  • Filed S-3 shelf for up to $400M in securities (debt, common, preferred, warrants, units)
  • Includes a $100M at-the-market (ATM) offering via Jefferies, up to 3% commission
  • Stock at $8.40, market cap ~$198M, shelf is 202% of market cap; ATM is ~50%
  • Auditors' report includes going concern uncertainty (Ernst & Young, FY2025 10-K)
  • Assuming $8.40/share, full ATM draw would issue ~11.9M shares (53% dilution vs 22.6M shares outstanding)
  • Net tangible book value per share was -$96.09; after full ATM draw would be -$55.04 per share
  • Proceeds for general corporate purposes, no specific use identified

Financial Impact

Up to $400M in potential dilution (~202% of current market cap); $100M ATM alone represents 53% dilution at $8.40/share

dilutioncapital structurestock price

Risk Factors

  • Dilution of up to 200%+ if full shelf is utilized
  • Going concern status, risk of bankruptcy if capital not raised
  • ATM sales will pressure stock price mechanically
  • No clear revenue growth to absorb dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-204130
Document: d69189dex41.htm0001193125-26-204130

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026